**AMENDED ABSTRACT**

Tigecycline Activity Tested against Resistant Surveillance Subsets of Clinical Bacteria Collected Worldwide (2011)

**INTRODUCTION**

Tigecycline was approved by the United States Food and Drug Administration (FDA) and Health Canada in 2005 for use in infections due to Gram-negative bacilli resistant to multiple antimicrobials, including broad-spectrum β-lactams, aminoglycosides, chloramphenicol, trimethoprim/sulfamethoxazole, and quinolones. The Tigecycline Activity Tested against Resistant Surveillance Subsets of Clinical Bacteria Collected Worldwide (2011) study was conducted in collaboration with the European Committee on Antimicrobial Susceptibility Testing (EUCAST) to determine the activity of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae. The study included 20,950 unique clinical isolates from 36 countries.

**MATERIALS AND METHODS**

**Conclusions:**

- The overall Tigecycline susceptibility rate was 95.7%, which was significantly higher than that of other agents tested.
- Tigecycline showed excellent activity against resistant Gram-positive organisms (MRSA, VRE, MDR-Staphylococcus and Gram-negative organisms (Enterobacteriaceae and non-fermenters) varied regionally, and compromise the use of the remaining antimicrobials.

- In the 2011 global SENTRY program, Tigecycline displayed demonstrated sustained potent activity across the regions when tested against clinically important bacteria causing infections worldwide, including MDR organism subsets.

**RESULTS**

- Tigecycline MIC50 were 4.93, 39.2, 2.9 and 27.0 µg/ml in NA, EU, LA and APAC, respectively. All MRSA were Tigecycline susceptible. Tigecycline was active against Enterobacteriaceae (96.7-98.9%), E. coli, Klebsiella, and vancomycin-resistant S. aureus (93.9%). Tigecycline was active against Enterobacteriaceae (86.8-91.9%) in APAC. Tigecycline was active against vancomycin-resistant enterococci (VRE) rate was 26.7% in global and Tigecycline showed excellent activity against non-S. aureus MRSA.

**ACKNOWLEDGMENT**

The authors would like to thank all participating centers worldwide for contributing to this study.

**Table 1.** MIC distribution and cumulative frequency (%) of tigecycline against bacterial pathogens (2011).

**Table 2.** Regional and global activity of tigecycline and comparator antimicrobial agents when tested against Gram-negative bacilli (2011).

---

*H.S. SADER, R.K. FLAMM, R.N. JONES*
JMI Laboratories, North Liberty, Iowa, USA